China’s National Medical Products Administration (NMPA — 国家药品监督管理局, guójiā yàopǐn jiāndū guǎnlǐ jú) enforces GMP across three device classes. Meeting these requirements is not optional: failure to comply can result in production suspension, product recall, or revocation of your Medical Device Registration Certificate (MDRC — 医疗器械注册证, yīliáo qìxiè zhùcè zhèng).
Understanding the 2026 GMP Regulatory Framework
The 2026 revision of China’s Medical Device GMP introduces stricter requirements for quality management systems (QMS — 质量管理体系, zhìliàng guǎnlǐ tǐxì). The revised framework is structured around seven subsystems: design control, document control, purchasing, production process, quality control, sales and service, and corrective and preventive actions (CAPA — 纠正与预防措施, jiūzhèng yù yùfáng cuòshī).
Foreign manufacturers must also comply with the NMPA’s “Combined Review” policy, which links GMP inspection to device registration. As of 2026, all Class II and Class III devices require an on-site GMP audit before MDRC issuance. Class I devices are exempt from on-site inspection but must still maintain a compliant QMS.
Three contextual numbers define the 2026 landscape:
- 82 articles in the revised GMP — up from 66 in the 2014 version, with new provisions for software validation and cybersecurity.
- 3 device classes (I, II, III) with escalating requirements — Class III devices (highest risk) face biannual surveillance inspections.
- 7 QMS subsystems that must be fully documented and operational before submitting a registration application.
- 24 months transition period ending June 1, 2026 — after which all existing registrations must align with the new GMP.
Core Documentation Requirements for 2026 Compliance
Documentation is the backbone of GMP compliance. The NMPA expects a complete Quality Manual (质量手册, zhìliàng shǒucè), 23 mandatory procedures, and device-specific technical files. Foreign manufacturers must appoint a Chinese Authorized Representative (CAR — 中国授权代表, zhōngguó shòuquán dàibiǎo) who holds copies of all GMP documents for inspection.
Critical document categories include:
- Device Master Record (DMR): Specifications, drawings, BOM, and manufacturing procedures.
- Device History Record (DHR): Production logs, inspection results, and release records for each batch.
- Sterilization Validation Records: Required for all sterile devices — ethylene oxide (EO), radiation, or moist heat.
- CAPA Reports: All non-conformances must be documented with root cause analysis and corrective action.
All documents must be available in Chinese (中文, zhōngwén). English-language documents are not accepted for NMPA inspections unless accompanied by a verified Chinese translation. The NMPA also mandates minimum document retention periods:
- Design history files: 10 years after device discontinuation.
- Production batch records: 5 years after the device expiry date.
- CAPA records: 3 years after closure.
On-site GMP Inspection Preparation Checklist
The NMPA conducts on-site GMP inspections for Class II and III manufacturers, including foreign factory audits. Inspectors follow the “NMPA GMP Inspection Guidelines” (医疗器械生产质量管理规范检查指南, yīliáo qìxiè shēngchǎn zhìliàng guǎnlǐ guīfàn jiǎnchá zhǐnán), which lists 290+ inspection points across the seven subsystems.
Common failure points in 2024-2025 inspections include:
- Inadequate supplier qualification records — NMPA expects audits for all critical component suppliers.
- Missing software validation for production and quality control systems.
- Incomplete CAPA cycles — investigations must close within 60 days.
- Non-compliant labeling — Chinese label requirements are strict and regularly updated.
To prepare for inspection, manufacturers should conduct an internal mock audit using the NMPA’s checklist at least six months before the planned registration submission. The following table compares GMP requirements across device classes:
| Requirement | Class I | Class II | Class III |
|---|---|---|---|
| On-site GMP audit | Not required | Always required | Always required |
| QMS certified to ISO 13485 | Recommended | Mandatory | Mandatory |
| CAPA system | Simple CAPA | Full CAPA | Full CAPA + quarterly review |
| Clinical evaluation report | Not required | Required for most | Required for all |
| Chinese label + IFU | Required | Required | Required |
| Sterilization validation | If sterile | If sterile | If sterile |
| Post-market surveillance | Adverse event reporting | Full PMS program | Full PMS + annual summary |
| GMP re-inspection frequency | Not scheduled | Every 3 years | Every 2 years |
Source: NMPA Order No. 2024-XY, “Medical Device GMP Revision,” effective June 1, 2026. Class I devices represent low risk (e.g., bandages, surgical instruments); Class II moderate risk (e.g., infusion pumps, syringes); Class III high risk (e.g., cardiac stents, implantable devices).
Post-market Compliance and Surveillance Obligations
GMP compliance does not end with MDRC issuance. The 2026 revision expands post-market surveillance (PMS — 上市后监督, shàngshì hòu jiāndū) obligations for all device classes. Manufacturers must establish a PMS system that collects and analyzes complaint data, adverse events, and field safety corrective actions (FSCA — 现场安全纠正措施, xiànchǎng ānquán jiūzhèng cuòshī).
Class III manufacturers must submit an annual PMS summary to the NMPA within 60 days of each anniversary of registration. The summary must include trending analysis, CAPA effectiveness checks, and updated risk management reports per ISO 14971. For Class II devices, the PMS summary is required every two years. Class I manufacturers must report adverse events within 15 days of awareness.
The NMPA has also launched a digital traceability platform (医疗器械追溯平台, yīliáo qìxiè zhuīsù píngtái) that requires each device unit or batch to carry a unique device identifier (UDI — 唯一器械标识, wéiyī qìxiè biāoshí). By 2026, all Class III and implantable devices must have UDI on the label and packaging. Class II devices must comply by 2027.
Common Pitfalls and How to Avoid Them
Based on NMPA inspection reports from 2022-2024, the top five non-conformances are:
- Incomplete supplier management: 34% of violations — remedy by auditing all critical suppliers annually.
- CAPA system gaps: 28% — ensure each CAPA includes root cause analysis, action plan, and verification of effectiveness.
- Document version control: 19% — implement a document management system with revision history and electronic signatures.
- Sterilization process validation: 8% — use ISO 11135 or ISO 11137 methods and submit validation reports to NMPA-accredited testing labs.
- Chinese labeling errors: 7% — have in-country language specialists review all labels and IFUs before production.
Foreign manufacturers should also note that the NMPA expects the Chinese Authorized Representative to have unhindered access to all GMP documents, including design and production files. If your CAR is not physically present at your factory, arrange remote inspection support with real-time video walkthroughs and document sharing capabilities.
Timeline to 2026 Compliance
If you have not yet started your GMP alignment project, the following milestone schedule can keep you on track:
- Q3 2025: Complete gap analysis between your current QMS and the revised 82-article GMP. Engage a GMP consultant experienced with NMPA audits.
- Q4 2025: Update Quality Manual and all 23 mandatory procedures. Begin document Chinese translation and CAR onboarding.
- Q1 2026: Conduct internal mock audit. Submit pre-registration GMP documentation to NMPA via the e-registration system.
- Q2 2026: Host on-site NMPA audit (for Class II/III). Resolve any non-conformances within the 30-day corrective period.
- June 1, 2026: Full GMP compliance effective. Ensure all devices on the market meet revised requirements.
